Fierce Biotech Summit 2024

For decades, pharmaceutical firms have relied on batch manufacturing, a method prone to inefficiencies and long hold times, and moved towards continuous manufacturing to reduce cycle times. As the cell therapy space increasingly moves away from small batches and looks to increase throughput and scale, we are now asking ourselves how we can also make the cell therapy supply chain a “continuous process” to address complexities and advance as an industry. This session explores the need for end-to-end solutions for cell therapy products including cGMP manufacturing supply chain considerations across the entire product lifecycle to enhance efficiency and cost-effectiveness and improve process consistency. Discover how cell therapy companies can achieve reductions in operating costs, waste, and cycle times while enhancing product quality to respond to market demands for these transformative therapies.